All In Biotech

Drug Trial Radar · NCT07479862

A Study of SA030 Injection in Overweight/Obese Participants With or Without Type 2 Diabetes Mellitus (T2DM)

A Randomized, Double-Blind, Placebo-Controlled Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of SA030 Injection in Overweight/Obese Participants With or Without Type 2 Diabetes Mellitus (T2DM)

Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Apr 16, 2026

Primary completion

Apr 24, 2028

Study completion Apr 24, 2028

Sponsor

Sponsor type
Industry
First posted
Mar 18, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is the first time the study drug, SA030, is being given to people. The main goal of this study is to find out if it is safe, how well people can tolerate it, how the body processes the drug, how the drug works, and whether it causes any immune reactions. The study has two parts. In Part 1, people who are overweight or have obesity will receive a single dose of the drug, starting with a low dose and slowly increasing it. In Part 2, people with obesity (with or without type 2 diabetes) will receive multiple doses over time. SA030 is being developed as a potential new treatment for people who are overweight or have obesity. Over the last few decades, more and more people around the world have become overweight or obese, and the numbers keep rising in almost every country. From 1990 to 2021, this problem grew steadily and reached its highest point in 2021.

Conditions

  • Obese
  • Overweight
  • T2DM (Type 2 Diabetes Mellitus)

Interventions

  • SA030 InjectionDrug

    Single dose, 5 dose levels; mulitple dose, 3 dose levels or 2 dose levels

  • Matching PlaceboDrug

    Single dose, matching placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with adverse events (AEs) and serious adverse events (SAEs)Time frame: Approximatly 12 months
  2. Number of participants with clinical significant laboratory abnormalitiesTime frame: Approximatly 12 months

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • CMAX Clinical Research Pty Ltd North Terrace

    Adelaide, Australia · Recruiting

  • Nucleus Network

    Brisbane, Queensland, Australia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.